Updated on September 21, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Sept. 8, 2022 (HealthDay News) -- An experimental drug that has been shown to treat rashes in people with lupus may also help with lupus-related joint pain.
Affecting as many as 1.5 million people in the United States, lupus is an autoimmune disease in which the body’s immune system misfires against its own joints, skin, brain, lungs, kidneys and blood vessels.
People with lupus who took litifilimab showed marked reductions in joint tenderness and swelling compared with people who took a placebo (or dummy medication), a clinical trial showed.
Given as a shot, the new drug is a monoclonal antibody. These are man-made molecules that target specific proteins on cells. In this case, the drug targets a protein called blood dendritic cell antigen 2 (BDCA2). This protein is found on plasmacytoid dendritic cells (PDCs), which produce inflammatory molecules including type 1 interferons.
“There’s a lot of evidence that interferon is important in lupus,” said study author Dr. Richard Furie. He is chief of rheumatology at Northwell Health in New Hyde Park, N.Y., and a professor at the Feinstein Institutes for Medical Research in Manhasset, N.Y.
“The antibody binds to BDCA2, the protein is internalized, and the synthesis of type 1 interferon is shut off,” he explained. “Litifilimab doesn't kill the cell: It just puts it to sleep.”
The new drug also seems to help cool other inflammatory proteins involved in lupus, but its chief effect is on type 1 interferon, Furie said.
For the study, 102 people with lupus who had at least four tender and four swollen joints received a 450 mg dose of litifilimab or a placebo for 24 weeks. The drug is given as a shot every four weeks.
Patients who took litifilimab had fewer swollen and tender joints than their counterparts who got the placebo, the investigators found.
In addition to improving joint symptoms, the new drug also improved skin rashes and had a “very robust” effect on a scale measuring overall lupus symptoms and activity, Furie said.
“This drug is very good for skin disease, and this robust response says it is good for global lupus too, not just arthritis,” he said. Drug maker Biogen sponsored the new trial.
Now, the new drug moves on to larger Phase 3 trials, to test safety and effectiveness. Then, Furie said, hopefully it continues its march toward U.S. Food and Drug Administration approval.
“The future is bright,” he said. “There’s a lot of drug development in lupus, and we are finally seeing success.”
Dr. Daniel Wallace, a rheumatologist and professor of medicine at Cedars-Sinai Medical Center in Los Angeles, wrote an editorial that accompanied the latest findings.
“The drug is promising for both systemic and cutaneous [skin] lupus,” Wallace said.
People who took the drug did have a higher risk of developing shingles, however.
“Patients would be advised to be immunized with shingles vaccine before [starting this drug],” Wallace said. This is also recommended for another lupus drug that was approved in August 2021 to target interferon.
More study is needed before litifilimab is approved, he said.
“The major questions to be investigated are, one, how the drug works in people of color who were underrepresented in the study, and secondly, how it works in patients with serious, organ-threatening disease,” Wallace said.
He noted that lupus disproportionately strikes people from racial and ethnic minority groups and they are also more likely to develop severe lupus.
Rheumatologist Dr. Jill Buyon is cautiously optimistic about the new drug and the current lupus drug pipeline. She is director of the Lupus Center at NYU Langone in New York City.
“I am swayed not just by the clinical data but by the mechanism, which is upstream of interferon signaling and more directly targeting the source,” she said of litifilimab.
It’s too early to know which people with lupus would respond best to the new drug, said Buyon, who has no ties to the new research.
“Arthritis is an unmet need in lupus, and we have not had a whole lot of success treating it," she said. “The new drug is exciting because it’s very targeted, seems to be quite effective for arthritis, and comes on the heels of the cutaneous [skin] study.”
More drugs for lupus are definitely needed as current ones only work in some people, some of the time, Buyon said.
The future of lupus treatment is expected to involve precision medicine or matching treatments to people based on very specific characteristics of their disease.
“We are now looking for mechanisms that will be more and more specific so we can use precision medicine in lupus for the first time,” she added.
The Lupus Research Alliance has more about lupus treatment.
SOURCES: Richard Furie, MD, professor, Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, N.Y., chief, division of rheumatology, Northwell Health, New Hyde Park, N.Y., advisor, Lupus Clinical Investigators Network, Lupus Research Alliance’s clinical affiliate Lupus Therapeutics; Daniel Wallace, MD, rheumatologist, professor, medicine, Cedars-Sinai Medical Center, Los Angeles; Jill Buyon, MD, rheumatologist, director, NYU Langone Lupus Center, New York City; New England Journal of Medicine, Sept. 8, 2022
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.